[go: up one dir, main page]

PE20040982A1 - Nuevos agonistas ppar alfa y ppar gamma - Google Patents

Nuevos agonistas ppar alfa y ppar gamma

Info

Publication number
PE20040982A1
PE20040982A1 PE2003000873A PE2003000873A PE20040982A1 PE 20040982 A1 PE20040982 A1 PE 20040982A1 PE 2003000873 A PE2003000873 A PE 2003000873A PE 2003000873 A PE2003000873 A PE 2003000873A PE 20040982 A1 PE20040982 A1 PE 20040982A1
Authority
PE
Peru
Prior art keywords
phenyl
methyl
lower alkyl
ppar
alkyl
Prior art date
Application number
PE2003000873A
Other languages
English (en)
Inventor
Peter Mohr
Alfred Binggeli
Hans-Peter Maerki
Hans Hilpert
Georges Hirth
Markus Meyer
Uwe Grether
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20040982A1 publication Critical patent/PE20040982A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE INVOLUCRAN UN COMPUESTO DE FORMULA I DONDE X ES N, S; Y ES S, N; R1 ES ARILO, HETEROARILO; R2 ES H, ALQUILO INFERIOR, FLUORO-ALQUILO INFERIOR; R3, R4, R5 Y R6 SON CADA UNO H, OH, ALQUENILO INFERIOR, ENTRE OTROS; R7 ES ALQUILO INFERIOR, ALCOXILO INFERIOR, ALQUENILOXILO INFERIOR, ENTRE OTROS; R8 ES H O ALQUILO INFERIOR; R9 Y R10 SON CADA UNO H, ALQUILO INFERIOR, ALQUENILO INFERIOR CICLOALQUILO, FENILO, ENTRE OTROS; n ES 1-3. COMPUESTOS PREFERIDOS SON: ACIDO [RAC]-2-ETOXI-3-{4-[2-(5-METIL-2-FENIL-TIAZOL-4-IL)-ETOXI]-BENZO[b]TIOFEN-7-IL}-PROPIONICO; ACIDO (2S)-3-{4-[2-(4-CLORO-FENIL)-TIAZOL-4-ILMETOXI]-2-METIL-FENIL}-2-ETOXI-PROPIONICO Y ACIDO 2-(4-{CICLOPROPIL-[4-METIL-2-(4-TRIFLUOROMETIL-FENIL)-TIAZOL-5-IL]-METOXI}-2-METIL-BENCIL)-BUTIRICO; ENTRE OTROS. SU UTILIDAD SE RELACIONA CON EL TRATAMIENTO DE DIABETES Y OTRAS ENFERMEDADES MODULADAS POR AGONISTAS PPARa Y/O PPARy
PE2003000873A 2002-08-30 2003-08-26 Nuevos agonistas ppar alfa y ppar gamma PE20040982A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02019146 2002-08-30

Publications (1)

Publication Number Publication Date
PE20040982A1 true PE20040982A1 (es) 2004-12-30

Family

ID=31970267

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000873A PE20040982A1 (es) 2002-08-30 2003-08-26 Nuevos agonistas ppar alfa y ppar gamma

Country Status (29)

Country Link
US (1) US6809110B2 (es)
EP (1) EP1537091B1 (es)
JP (2) JP4533141B2 (es)
KR (1) KR100736955B1 (es)
CN (1) CN100475810C (es)
AR (1) AR041079A1 (es)
AT (1) ATE483699T1 (es)
BR (1) BR0313946A (es)
CA (1) CA2495942C (es)
DE (1) DE60334461D1 (es)
DK (1) DK1537091T3 (es)
ES (1) ES2350340T3 (es)
GT (1) GT200300183A (es)
HR (1) HRP20050158A2 (es)
IL (1) IL166833A (es)
MX (1) MXPA05002115A (es)
MY (1) MY141020A (es)
NO (1) NO329777B1 (es)
NZ (1) NZ537897A (es)
PA (1) PA8581201A1 (es)
PE (1) PE20040982A1 (es)
PL (1) PL375779A1 (es)
PT (1) PT1537091E (es)
RU (1) RU2296754C2 (es)
SI (1) SI1537091T1 (es)
TW (1) TWI338686B (es)
UY (1) UY27959A1 (es)
WO (1) WO2004020420A1 (es)
ZA (1) ZA200501097B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
ES2350340T3 (es) * 2002-08-30 2011-01-21 F. Hoffmann-La Roche Ag Nuevos compuestos de 2-aril-tiazol como agonistas de pparalfa y ppargamma.
GB0405033D0 (en) * 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
JP2009084156A (ja) * 2006-01-18 2009-04-23 Nissan Chem Ind Ltd チアゾール置換アセトニトリルの製造方法
ZA200809148B (en) * 2006-04-18 2010-01-27 Nippon Chemiphar Co Activating agent for peroxisome proliferator activated receptor delta
AU2008221718A1 (en) * 2007-03-07 2008-09-12 Dong-A Pharm. Co., Ltd. Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
WO2008108602A1 (en) * 2007-03-07 2008-09-12 Dong-A Pharm. Co., Ltd. Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
DE102007038251A1 (de) * 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
CN101928259B (zh) * 2009-06-18 2012-10-03 南京海辰药业有限公司 2-芳基噻唑衍生物及其药物组合物
CN102285933B (zh) * 2010-06-18 2016-03-09 浙江海正药业股份有限公司 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用
CN102351852B (zh) * 2011-08-23 2014-06-18 上海交通大学 苯并呋喃类化合物及其制备方法、用途
ES2861268T3 (es) 2011-09-20 2021-10-06 Basf Se Moduladores de bajo peso molecular del receptor de mentol frío TRPM8 y su uso
US20190350955A1 (en) 2016-06-30 2019-11-21 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods and pharmaceutical compositions for the treatment of cardiomyopathies
EP3595777A4 (en) * 2017-03-14 2021-01-20 Dana-Farber Cancer Institute, Inc. LOW MOLECULAR SENSITIVITY OF BAX ACTIVATION FOR INDUCING CELL DEATH
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
CN115894379B (zh) * 2022-01-20 2025-06-27 哈尔滨三联药业股份有限公司 海因类化合物及其医药用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1237194A (en) * 1967-10-26 1971-06-30 Wyeth John & Brother Ltd Pharmaceutical compositions containing 2-arylthiazoles
US4011326A (en) 1975-07-29 1977-03-08 Merck & Co., Inc. 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents
US4560690A (en) * 1984-04-30 1985-12-24 Pfizer Inc. 2-(N-substituted guanidino)-4-hetero-arylthiazole antiulcer agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1994001420A1 (en) * 1992-07-03 1994-01-20 Smithkline Beecham Plc Heterocyclic compounds as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
DK124393D0 (da) * 1993-11-03 1993-11-03 Lundbeck & Co As H Compounds
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
TW476758B (en) 1996-12-10 2002-02-21 Bristol Myers Squibb Co Benzodioxole, benzofuran, dihydrobenzofuran and benzodioxane melatonergic agents
DE19711616A1 (de) 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6121397A (en) 1997-07-14 2000-09-19 Xerox Corporation Polymerization processes using oligomeric compound, monomer and surfactant
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
EP0903343B1 (en) 1997-09-19 2003-05-28 SSP Co., Ltd. Alpha-Substituted phenylpropionic acid derivative and medicine containing the same
HUP0101366A2 (hu) * 1997-12-19 2001-09-28 Merck & Co., Inc. Aril-tiazolidin-dion-származékok, eljárás az előállításukra és e vegyületeket tartalmazó gyógyászati készítmények
US6008237A (en) * 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
EP1073643B1 (en) 1998-04-23 2004-12-29 Dr. Reddy's Laboratories Ltd. New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
WO2000078314A1 (en) * 1999-06-18 2000-12-28 Merck & Co., Inc. Process for making arylthiazolidinedione derivatives
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
ATE319702T1 (de) 1999-08-02 2006-03-15 Verfahren zur herstellung von benzothiophen- derivaten
JP2001261612A (ja) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬
CN1471517A (zh) * 2000-08-23 2004-01-28 Cxazolyl-芳基丙酸衍生物及其作为过氧化物酶体增殖物活化受体激动剂的用途
MXPA03010435A (es) * 2001-05-15 2004-03-09 Hoffmann La Roche Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
WO2003072102A1 (en) * 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
ES2350340T3 (es) * 2002-08-30 2011-01-21 F. Hoffmann-La Roche Ag Nuevos compuestos de 2-aril-tiazol como agonistas de pparalfa y ppargamma.

Also Published As

Publication number Publication date
EP1537091A1 (en) 2005-06-08
NO329777B1 (no) 2010-12-13
CN1678596A (zh) 2005-10-05
JP2010132671A (ja) 2010-06-17
DK1537091T3 (da) 2010-11-08
JP2006502151A (ja) 2006-01-19
HK1082504A1 (zh) 2006-06-09
TWI338686B (en) 2011-03-11
CA2495942C (en) 2010-03-23
RU2296754C2 (ru) 2007-04-10
DE60334461D1 (de) 2010-11-18
PL375779A1 (en) 2005-12-12
ZA200501097B (en) 2006-11-29
IL166833A (en) 2010-12-30
ES2350340T3 (es) 2011-01-21
US20040110807A1 (en) 2004-06-10
BR0313946A (pt) 2005-07-12
HRP20050158A2 (en) 2006-11-30
AR041079A1 (es) 2005-04-27
RU2005109163A (ru) 2006-01-20
US6809110B2 (en) 2004-10-26
CN100475810C (zh) 2009-04-08
MXPA05002115A (es) 2005-05-23
PT1537091E (pt) 2010-11-11
GT200300183A (es) 2004-04-15
PA8581201A1 (es) 2004-09-16
KR100736955B1 (ko) 2007-07-09
NO20050620L (no) 2005-03-03
ATE483699T1 (de) 2010-10-15
MY141020A (en) 2010-02-25
AU2003273801A1 (en) 2004-03-19
EP1537091B1 (en) 2010-10-06
UY27959A1 (es) 2004-02-27
TW200407133A (en) 2004-05-16
JP4533141B2 (ja) 2010-09-01
KR20050057083A (ko) 2005-06-16
NZ537897A (en) 2007-08-31
WO2004020420A1 (en) 2004-03-11
SI1537091T1 (sl) 2010-12-31
CA2495942A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
PE20040982A1 (es) Nuevos agonistas ppar alfa y ppar gamma
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
JO2537B1 (en) Aryl-pyridine or pyrezinate compounds replaced with heterogeneous pentagonal rings used as inhibitors of MTB proteins
PE20120008A1 (es) Derivados de fenoxi bencenosulfonamida
PE20090708A1 (es) Compuestos y composiciones como moduladores de la actividad gpr119
PE20142400A1 (es) Compuestos novedosos
PE20040666A1 (es) Derivados novedosos de piperidina
NZ591172A (en) Compounds for the treatment of hepatitis c
PE20091343A1 (es) Compuestos derivados de heterociclo biciclicos como moduladores de gpr119
DK1258484T3 (da) Nye isoxazol- og thiazolforbindelser og anvendelse deraf som lægemidler
BRPI0509364B8 (pt) derivados de tetraidroquinolina, composição farmacêutica que os compreende e um processo por preparar os referidos derivados
BRPI0409429A (pt) ácido carboxìlico substituìdo na posição alfa como moduladores ppar
AR033349A1 (es) Compuesto heterociclico y composicion farmaceutica, agente hipoglucemico, agente hipolipidemico, mejorador de la resistencia a la insulina, agente terapeutico para las complicaciones de origen diabetico y agente terapeutico para la diabetes que los comprenden
PE20081059A1 (es) Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk)
PE20090641A1 (es) Amidas heterociclicas
PE20011313A1 (es) Activadores de glucoquinasa que contienen hidantoina
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
ATE537169T1 (de) Piperidin- und piperazinderivate als p2x3- antagonisten
PE20050872A1 (es) Compuestos 5-fenil-tiazol-2-il-amida como inhibidores de la enzima fosfatidilinositol 3-cinasa
PE20080364A1 (es) Acido bifenilcarboxilicos substituidos y sus derivados como moduladores de la actividad de la gamma-secretasa
GB0428514D0 (en) Compounds
AR066781A1 (es) Compuestos de imidazopirimidina inhibidores de cinasa
PE20120657A1 (es) Compuesto para el tratamiento de trastornos metabolicos
AR073609A1 (es) COMPUESTOS DE ANILLO FUSIONADO Y USO DE LOS MISMOS EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVACIoN DE LA GLUCOQUINASA.
NO20045222L (no) Benzosyrederivater som modulatorer av PPAR alfa og gamma

Legal Events

Date Code Title Description
FC Refusal